Literature DB >> 6257926

Abelson murine leukemia virus mutants deficient in kinase activity and lymphoid cell transformation.

N E Rosenberg, D R Clark, O N Witte.   

Abstract

Abelson murine leukemia virus transforms both lymphoid cells and fibroblasts in vitro and induces a unique type of thymus-dependent lymphoma in vivo. Four fibroblast-transforming strains of Abelson murine leukemia virus were identified, based on the sizes of the Abelson murine leukemia virus-specific phosphoproteins produced by these isolates. Two of these strains, the standard P120- and the P160-producing viruses, transformed lymphoid cells efficiently in vitro and induced Abelson disease in vivo. Two other strains, which synthesized small Abelson murine leukemia virus-specific proteins with molecular weights of 90,000 (P90) and 100,000 (P100), transformed lymphoid cells very poorly both in vitro and in vivo. The reduced oncogenic potentials of these isolates were correlated with a high level of synthesis of fairly unstable P90 and P100. In addition, neither P90 nor P100 functional efficiently in protein kinase assays. The correlation of abnormal metabolism and deficient protein kinase activity with the reduced oncogenic potentials of these virus strains supported a direct role for these proteins and the kinase activity in transformation. Furthermore, these results suggested that the requirements for lymphoid cell transformation and fibroblast transformation are different.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6257926      PMCID: PMC353704     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  22 in total

1.  Direct transformation of 3T3 cells by Abelson murine leukaemia virus.

Authors:  C D Scher; R Siegler
Journal:  Nature       Date:  1975-02-27       Impact factor: 49.962

2.  In vitro transformation of lymphoid cells by Abelson murine leukemia virus.

Authors:  N Rosenberg; D Baltimore; C D Scher
Journal:  Proc Natl Acad Sci U S A       Date:  1975-05       Impact factor: 11.205

3.  Protein kinase activity associated with the avian sarcoma virus src gene product.

Authors:  M S Collett; R L Erikson
Journal:  Proc Natl Acad Sci U S A       Date:  1978-04       Impact factor: 11.205

4.  Identification of an Abelson murine leukemia virus-encoded protein present in transformed fibroblast and lymphoid cells.

Authors:  O N Witte; N Rosenberg; M Paskind; A Shields; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1978-05       Impact factor: 11.205

5.  Lymphosarcoma: virus-induced thymic-independent disease in mice.

Authors:  H T Abelson; L S Rabstein
Journal:  Cancer Res       Date:  1970-08       Impact factor: 12.701

6.  Rapid cell culture assay technic for murine leukaemia viruses.

Authors:  R H Bassin; N Tuttle; P J Fischinger
Journal:  Nature       Date:  1971-02-19       Impact factor: 49.962

7.  Amphotropic host range of naturally occuring wild mouse leukemia viruses.

Authors:  S Rasheed; M B Gardner; E Chan
Journal:  J Virol       Date:  1976-07       Impact factor: 5.103

8.  Relationship of retrovirus polyprotein cleavages to virion maturation studied with temperature-sensitive murine leukemia virus mutants.

Authors:  O N Witte; D Baltimore
Journal:  J Virol       Date:  1978-06       Impact factor: 5.103

9.  Effect of pseudotype on Abelson virus and Kirsten sarcoma virus-induced leukemia.

Authors:  C D Scher
Journal:  J Exp Med       Date:  1978-04-01       Impact factor: 14.307

10.  The effect of helper virus on Abelson virus-induced transformation of lymphoid cells.

Authors:  N Rosenberg; D Baltimore
Journal:  J Exp Med       Date:  1978-04-01       Impact factor: 14.307

View more
  42 in total

1.  Insertional mutagenesis of the Abelson murine leukemia virus genome: identification of mutants with altered kinase activity and defective transformation ability.

Authors:  R W Rees-Jones; S P Goff
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

2.  Carboxyl-terminal determinants of Abelson protein important for lymphoma induction.

Authors:  K Parmar; R C Huebner; N Rosenberg
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

3.  Isolation of temperature-sensitive Abelson virus mutants by site-directed mutagenesis.

Authors:  A Engelman; N Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

4.  Use of site-specific antipeptide antibodies to perturb the serine kinase catalytic activity of p37mos.

Authors:  S A Maxwell; R B Arlinghaus
Journal:  J Virol       Date:  1985-09       Impact factor: 5.103

5.  The carboxyl terminus of v-Abl protein can augment SH2 domain function.

Authors:  D Warren; A J Heilpern; K Berg; N Rosenberg
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

6.  p53 deficiency increases transformation by v-Abl and rescues the ability of a C-terminally truncated v-Abl mutant to induce pre-B lymphoma in vivo.

Authors:  X Zou; F Cong; M Coutts; G Cattoretti; S P Goff; K Calame
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

7.  En bloc substitution of the Src homology region 2 domain activates the transforming potential of the c-Abl protein tyrosine kinase.

Authors:  A J Muller; A M Pendergast; K Parmar; M H Havlik; N Rosenberg; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

8.  Some lymphoid cell lines transformed by Abelson murine leukemia virus lack a major 36,000-dalton tyrosine protein kinase substrate.

Authors:  B M Sefton; T Hunter; J A Cooper
Journal:  Mol Cell Biol       Date:  1983-01       Impact factor: 4.272

9.  Abelson murine leukemia virus: structural requirements for transforming gene function.

Authors:  A Srinivasan; C Y Dunn; Y Yuasa; S G Devare; E P Reddy; S A Aaronson
Journal:  Proc Natl Acad Sci U S A       Date:  1982-09       Impact factor: 11.205

10.  Only site-directed antibodies reactive with the highly conserved src-homologous region of the v-abl protein neutralize kinase activity.

Authors:  J B Konopka; R L Davis; S M Watanabe; A S Ponticelli; L Schiff-Maker; N Rosenberg; O N Witte
Journal:  J Virol       Date:  1984-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.